PDS Biotechnology (PDSB) Change in Account Payables (2014 - 2025)

PDS Biotechnology (PDSB) has 12 years of Change in Account Payables data on file, last reported at -$1.6 million in Q4 2025.

• Quarterly Change in Account Payables fell 518.41% year-over-year to -$1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (up 135.67% YoY) and the FY2025 annual result came in at $1.9 million, up 135.67% from the prior year.
• Change in Account Payables retreated to -$1.6 million in Q4 2025, from $683494.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.3 million in Q2 2023 to a low of -$2.7 million in Q2 2024.
• A 5-year average of $107961.2 and a median of $271673.5 in 2022 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2023 — Change in Account Payables jumped 497.03% — and 2025, when it tumbled 518.41%.
• Tracing PDSB's Change in Account Payables over 5 years: stood at -$136182.0 in 2021, then sank by 500.74% to -$818103.0 in 2022, then soared by 297.56% to $1.6 million in 2023, then plunged by 76.24% to $383948.0 in 2024, then plunged by 518.41% to -$1.6 million in 2025.
• The last three Change in Account Payables figures came in at -$1.6 million (Q4 2025), $683494.0 (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.